Kadmon Holdings, Inc. (NYSE:KDMN) Files An 8-K Other Events

ITEM8.01

On June 23, 2017, Kadmon Holdings, Inc. (the Company) issued a
press release announcing that the Company will present interim
data from its ongoing Phase 2 clinical trial of KD025, the
Companys lead ROCK2 inhibitor, in previously treated patients
with chronic graft-versus-host disease.The data will be presented
at Kadmons Research and Development Day in New York City on
Tuesday, July 11, 2017, from 8:45 a.m. to 11:00 a.m. ET. The full
text of the press release is attached to this Current Report on
Form 8-K as Exhibit 99.1.

(d) Exhibits.

Kadmon Holdings, Inc. Exhibit
EX-99.1 2 kdmn-20170623xex99_1.htm EX-99.1 991 Press Release Exhibit 99.1  Kadmon to Present Interim Data on KD025 in Chronic Graft-Versus-Host Disease (cGVHD) at R&D Day  — Event on July 11 in New York City with Live Webcast —  NEW YORK,…
To view the full exhibit click here
About Kadmon Holdings, Inc. (NYSE:KDMN)

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.